Easy, effective therapy to restore sight: Engineered virus will improve gene therapy for blinding eye diseases

June 12, 2013, University of California - Berkeley
To evolve the virus best suited for gene therapy, more than 100 million engineered adeno-associated viruses (left) are injected into the gel-like center of the eye. Those able to penetrate the many cell layers of the retina are used to shuttle a corrective gene into cells with a defective gene, in particular the light-sensitive photoreceptors and the retinal pigment epithelium cells. To reach these cells, the virus must pass through the retinal ganglion cells and the inner nuclear layer (right). Credit: David Schaffer lab, UC Berkeley

Researchers at the University of California, Berkeley, have developed an easier and more effective method for inserting genes into eye cells that could greatly expand gene therapy to help restore sight to patients with blinding diseases ranging from inherited defects like retinitis pigmentosa to degenerative illnesses of old age, such as macular degeneration.

Unlike current treatments, the new procedure – which takes a little as 15-minutes – is surgically non-invasive, and it delivers normal to difficult-to-reach cells throughout the entire .

Over the last six years, several groups have successfully treated people with a rare inherited by injecting a virus with a normal gene directly into the retina of an eye with a defective gene. Despite the invasive process, the virus with the normal gene was not capable of reaching all the that need fixing.

"Sticking a needle through the retina and injecting the engineered virus behind the retina is a risky surgical procedure," said David Schaffer, professor of chemical and biomolecular engineering and director of the Berkeley Stem Cell Center at the University of California, Berkeley. "But doctors have no choice because none of the gene delivery viruses can travel all the way through the back of the eye to reach the – the that need the therapeutic gene."

"Building upon 14 years of research, we have now created a virus that you just inject into the liquid vitreous humor inside the eye and it delivers genes to a very difficult-to-reach population of delicate cells in a way that is surgically non-invasive and safe. It's a 15-minute procedure, and you can likely go home that day."

The engineered virus works far better than current therapies in rodent models of two human , and can penetrate photoreceptor cells in the eyes of monkeys, which are like those of humans.

Schaffer and his team are now collaborating with physicians to identify the patients most likely to benefit from this technique and, after some preclinical development, hope soon to head into clinical trials, he said.

Schaffer and John Flannery, UC Berkeley professor of molecular and cell biology and of optometry, along with colleagues from UC Berkeley's Helen Wills Neuroscience Institute and the Flaum Eye Institute at the University of Rochester in New York, published the results of their study today (Wednesday, June 12) in the journal Science Translational Medicine.

Harnessing a benign virus for gene therapy

Three groups of researchers have successfully restored some sight to more than a dozen people with a rare disease called Leber's congenital amaurosis, which leads to complete loss of vision in early adulthood. They achieved this by inserting a corrective gene into adeno-associated viruses (AAV), a common but benign respiratory virus, and injecting the viruses directly into the retina. The take up the virus and incorporate the functional gene into their chromosomes to make a critical protein that the could not, rescuing the photoreceptors and restoring sight.

Unfortunately, the technique cannot be applied to most blinding diseases because the needle often causes retinal detachment, making the situation worse. Yet the standard AAV used in eye and other types of cannot penetrate into tissue to reach the photoreceptors and other cells, such as retinal pigment epithelium, that need to be fixed. The retina is about 100,000 times thicker than AAV, which is about 20 nanometers across.

Years ago, Schaffer set out to find a way to "evolve" AAV to penetrate tissues, including eye and liver, as a way to deliver genes to specific cells. To date he has generated 100 million variants of AAV – each carrying slightly different proteins on its coat – from which he and his colleagues selected five that were effective in penetrating the retina. They then used the best of these (7m8) to transport genes to cure two types of hereditary blindness for which there are mouse models: X-linked retinoschisis, which strikes only boys and makes their retinas look like Swiss cheese; and Leber's congenital amaurosis. In each case, when injected into the vitreous humor, the AAV delivered the corrective gene to all areas of the retina and restored retinal cells nearly to normal.

When injected into the eye of a normal monkey, the virus penetrated cells spottily across the retina but almost completely in the very important fine-vision area called the fovea. Current viruses do not penetrate foveal cells at all.

Schaffer predicts that the virus can be used not only to insert genes that restore function to non-working genes, but can knock out genes or halt processes that are actively killing retina , which may be the case in age-related .

"When I first got here 14 years ago, I really had the idea or the goal that I wanted to work on problems that would have direct impact on human health, and we are now getting there," Schaffer said.

Explore further: Study demonstrates potential of new gene vector to broaden treatment of eye diseases

More information: "In Vivo–Directed Evolution of a New Adeno-Associated Virus for Therapeutic Outer Retinal Gene Delivery from the Vitreous," by D. Dalkara et al. Science Translational Medicine, 2013.

Related Stories

Study demonstrates potential of new gene vector to broaden treatment of eye diseases

June 22, 2011
Inspired by earlier successes using gene therapy to correct an inherited type of blindness, investigators from the Perelman School of Medicine at the University of Pennsylvania, are poised to extend their approach to other ...

Two novel treatments for retinitis pigmentosa move closer to clinical trials

December 20, 2012
Two recent experimental treatments—one involving skin-derived induced pluripotent stem (iPS) cell grafts, the other gene therapy—have been shown to produce long-term improvement in visual function in mouse models of retinitis ...

Altering eye cells may one day restore vision

January 25, 2013
(Medical Xpress)—Doctors may one day treat some forms of blindness by altering the genetic program of the light-sensing cells of the eye, according to scientists at Washington University School of Medicine in St. Louis.

Algae may be the solution to blindness

April 15, 2011
(PhysOrg.com) -- The song about three blind mice may just be a song of the past according to new research presented by neuroscientist Alan Horsager from the Institute of Genetic Medicine at the University of Southern California ...

Recommended for you

Study advances gene therapy for glaucoma

January 16, 2018
While testing genes to treat glaucoma by reducing pressure inside the eye, University of Wisconsin-Madison scientists stumbled onto a problem: They had trouble getting efficient gene delivery to the cells that act like drains ...

New study offers added hope for patients awaiting corneal transplants

January 9, 2018
New national research led by Jonathan Lass of Case Western Reserve University School of Medicine has found that corneal donor tissue can be safely stored for 11 days before transplantation surgery to correct eye problems ...

Diabetic blindness caused and reversed "trapped" immune cells in rodent retinas

January 3, 2018
Johns Hopkins researchers have discovered a cell signaling pathway in mice that triggers vision loss in patients with diabetic retinopathy and retinal vein occlusion – diseases characterized by the closure of blood vessels ...

Ophthalmologists increasingly dissatisfied with electronic health records

December 29, 2017
Ophthalmologists' use of electronic health records (EHR) systems for storing and accessing patients' medical histories more than doubled between 2006 and 2016, while their perceptions of financial and clinical productivity ...

Higher omega-3 fatty acid intake tied to lower glaucoma risk

December 26, 2017
(HealthDay)—Increased daily intake of ω-3 fatty acids is associated with lower odds of glaucoma, but higher levels of total polyunsaturated fatty acid (PUFA) intake are associated with higher odds of developing glaucoma, ...

Protein analysis allows for treatment of eye-disease symptoms with existing drugs

December 21, 2017
Demonstrating the potential of precision health, a team led by a researcher at the Stanford University School of Medicine has matched existing drugs to errant proteins expressed by patients with a rare eye disease.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.